Research has demonstrated that the BRAF V600E mutation occurs in approximately 50% of LCH cases, while abnormal activation of MAPK pathway-related genes (e.g., MAP2K1 and ARAF) has also been confirmed to contribute to disease progression and drug resistance (4). This evidence concerns the gene BRAF and Langerhans cell histiocytosis.